What is RDD Pharma?
RDD Pharma operates with a distinct business model focused on the fast-track development and commercialization of novel therapeutics for challenging anorectal and gastrointestinal conditions. By strategically repurposing approved drugs and integrating proprietary drug-delivery technology, the company aims to navigate a shorter regulatory pathway. Their pipeline includes promising treatments for conditions such as fecal incontinence and pruritus ani, with a compound in preclinical development targeting radiation proctitis. This approach positions RDD Pharma in a lucrative market segment between generic medications and entirely new chemical entities, with molecules anticipated to reach the market within a 2 to 6-year timeframe.
How much funding has RDD Pharma raised?
RDD Pharma has raised a total of $17.9M across 3 funding rounds:
Series A
$7.2M
Grant
$1.3M
Series B
$9.5M
Series A (2012): $7.2M with participation from Orbimed
Grant (2017): $1.3M led by Department of Defense
Series B (2017): $9.5M supported by OrbiMed and Pharmascience, Inc
Key Investors in RDD Pharma
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various development stages, from early-stage ventures to established organizations, with a hands-on approach to strategic initiatives and operational optimization.
Pharmascience, Inc
Pharmascience, Inc. is a pharmaceutical manufacturer founded in 1983, specializing in both generic and branded drugs. Headquartered in Montreal, Quebec, the company plays a significant role in the drug production and supply chain.
Department of Defense
The U.S. Department of Defense is the federal department responsible for national security and the United States Armed Forces. Established in 1947, it oversees defense policy, military operations, and the development of advanced security technologies.
What's next for RDD Pharma?
The recent major strategic investment signals a pivotal growth phase for RDD Pharma, likely moving the company from its development stage towards scaling operations and advancing its pipeline candidates through clinical trials and regulatory approvals. This capital infusion is critical for RDD Pharma to further its mission of addressing unmet medical needs in niche gastrointestinal and anorectal disease areas. The company's focus on a low-risk, high-reward strategy, leveraging existing drug approvals, positions it favorably for future market penetration and potential partnerships within the pharmaceutical industry.
See full RDD Pharma company page
